This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Charles River Associates (CRA) Expands Global Life Sciences Offering

Stocks in this article: CRAI

Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing management, economic, and financial consulting services, today announced that Mark Beards has joined the firm as a vice president in the Life Sciences Practice based in London. Mr. Beards most recently led European healthcare equity research at Goldman Sachs in London. Prior to that, he was a consultant at McKinsey & Company and worked in commercial and research roles at leading, global pharmaceutical companies.

“Mark Beards’ expansive background—as an equity analyst in capital markets covering European life sciences companies, a strategy consultant advising large cap pharmaceutical organizations, and a business manager with direct sector experience—makes him a valuable addition to CRA,” said CRA's President and Chief Executive Officer Paul Maleh. “His deep knowledge base and practical approach allow for advising and problem-solving on a range of issues confronting life sciences companies. It is a pleasure to welcome him to CRA, where he will play an important role within our global life sciences offering.”

Mr. Beards has 20 years of experience in the life sciences and financial sectors. His specialties include commercialization, R&D, licensing, and setting corporate and product strategy. He has transformed underperforming business units into highly successful ones; developed licensing strategies to direct business development priorities; led due diligence, negotiations, and deal structures for licensing agreements; constructed go-to market strategies; and redesigned global marketing functions.

In his most recent role at Goldman Sachs, Mr. Beards was Vice President, Head of Equity Research, European Healthcare, and was responsible for coverage of the pharmaceutical, medical technology, and biotechnology sectors. He was the primary analyst on diversified pharmaceutical companies with a combined market capitalization of $335 billion. At McKinsey & Company, he focused on life sciences and advised global pharmaceutical companies in such areas as corporate strategy development, corporate transformation, product launch strategy, distribution valuation, consumer segmentation, and brand positioning. Prior to this role, Mr. Beards spent 11 years in business development and commercial strategy roles at Abbott Laboratories and GlaxoSmithKline, respectively. He began his career as an accountant and is a Chartered Management Accountant, ACMA. He holds a Diploma in Business Management from Henley Management College and a BA (Hons) degree and an MA degree in Mathematics from The Queen’s College, Oxford.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs